Biliary tract cancer

Current Opinion in Gastroenterology

Volumn 15, Issue 5, 1999, Pages 430-435

  Ehrenfried, John A ^a   Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR; VASCULOTROPIN;

ABDOMINAL WALL; ANGIOGENESIS; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; COMPUTER ASSISTED TOMOGRAPHY; GALLBLADDER CARCINOMA; HUMAN; LAPAROSCOPIC SURGERY; ONCOGENE; POLYP; PROGNOSIS; SURGICAL DRAINAGE; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

EID: 0032814015     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199909000-00010     Document Type: Article

References (43)

1. 1 Nakamura T, Nisnizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al.: Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342:440-443.
2. 2 Weidner KM, Arakaki N, Hartmann G, Vandekerckhove J, Weingart S, Rieder H, et al.: Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A 1991, 88:7001-7005.
3. 3 Stoker M, Gherardi E, Perryman M, Gray J: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987, 327:239-242.
4. 4 Li H, Shimura H, Aoki Y, Date K, Matsumoto K, Nakamura T, Tanaka M: Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. Clin Exp Metastasis 1998, 16:74-82.
5. 5 Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T: Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998, 17:3045-3054.
6. 6 Wistuba H, Miquel JF, Gazdar AF, Albores-Saavedra J: Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999, 30:21-25. In this paper, the adenoma-carcinoma sequence proposed for gallbladder carcinoma is refuted on the basis of a detailed analysis of molecular abnormalities in adenoma, dysplasia, and gallbladder carcinoma.
7. 7 Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995, 55:237-241.
8. 8 Josephs MD, Vauthey JN: Biliary tract cancer. Curr Opin Gastroenterol 1998, 14:402-407.
9. 9 Mikami T, Yanagisawa N, Baba H, Koike M, Okayasu I: Association of bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. Cancer 1999, 85:318-325.
10. 10 Czubayko F, Smith RV, Chung HC, Wellstein A: Tumor growth and angio-genesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem 1994, 269:28243-28248.
11. 11 Okita S, Kondoh S, Shiraishi K, Kaino S, Hatano S, Okita K: Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int J Oncol 1998, 12:1013-1018.
12. 12 Willman CL: Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Leukemia 1996, 10(suppl 1):S33-S35.
13. 13 Cao L, Duchrow M, Windhövel U, Kujath P, Bruch H-P, Broll R: Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues. Eur J Cancer 1998, 34:1612-1617.
14. 14 Masumoto N, Nakano S, Fujishima H, Kohno K, Niho Y: V-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Int J Cancer 1999, 80:731-737.
15. 15 Matsumoto K, Fujii H, Michalopoulos G, Fung JJ, Demetris AJ: Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor, and epidermal growth factor promote DNA synthesis in vitro. Hepatology 1994, 20:376-382.
16. 16 Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE: Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998, 227:398-404.
17. 17 Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regula tor. Science 1991, 251:1451-1455.
18. 18 Ashida K, Terada T, Kitamura Y, Kaibara N: Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 1998, 27:974-982.
19. 19 Meerson NR, Delautier D, Durand-Schneider A-M, Moreau A, Schilsky ML, Sternlieb I, et al.: Identification of B10, an alkaline phosphodiesterase of the apical plasma membrane of hepatocytes and biliary cells, in rat serum: increased levels following bile duct ligation and during the development of cholangiocarcinoma. Hepatology 1998, 27:563-568.
20. 20 Shukla VK, Aryya NC, Pitale A, Pandey M, Dixit VK, Reddy CD, Gautam A: Metallothionein expression in carcinoma of the gallbladder. Histopathology 1998, 33:154-157.
21. 21 Templeton DM, Cherian MG: Toxicological significance of metallothionein. Methods Enzymol 1991, 205:11-24.
22. 22 Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988, 241:1813-1815.
23. 23 Bach AM, Loring LA, Hann LE, Illescas FF, Fong Y, Blumgart LH: Gallbladder cancer: can ultrasonography evaluate extent of disease? J Ultrasound Med 1998, 17:303-309.
24. 24 Tillich M, Mischinger H-J, Preisegger K-H, Rabl H, Szolar DH: Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol 1998, 171:651-658.
25. 25 Feydy A, Vilgrain V, Denys A, Sibert A, Belghiti J, Vullierme M-P, Menu Y: Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings. AJR 1999, 172:73-77. Helical CT does contribute to evaluation of the proximal extent of hilar cholangiocarcinoma.
26. 26 Furukawa H, Kosuge T, Shimada K, Yamamoto J, Kanai Y, Mukai K, et al.: Small polypoid lesions of the gallbladder: differential diagnosis and surgical indications by helical computed tomography. Arch Surg 1998, 133:735-739. This paper presents a CT-based algorithm for the management of polypoid lesions of the gallbladder.
27. 27 Koga A, Watanabe K, Fukuyama T, Takiguchi S, Nakayama F: Diagnosis and operative indications for polypoid lesions of the gallbladder. Arch Surg 1988, 123:26-29.
28. 28 Burke EC, Jarnagin WR, Hochwald SN, Pisters PWT, Fong Y, Blumgart LH: Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998, 228:385-394. The patterns of spread and the value of hepatic resection in cholangiocarcinoma are evaluated. A preclinical staging system is proposed.
29. 29 Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I, et al.: Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998, 187:358-364.
30. 30 Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE: Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg 1998, 227:70-79.
31. 31 Jonas S, Kling N, Guckelberger O, Keck H, Bechstein WO, Neuhaus P: Orthotopic liver transplantation after extended bile duct resection as treatment of hilar cholangiocarcinoma: first long-term results. Transpl Int 1998, 11(suppl 1):S206-S208.
32. 32 Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, et al.: The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg 1998, 227:405-411. This detailed analysis of the histopathologic patterns of spread of hilar cholangiocarcinomas is based on tumor type.
33. 33 Bhuiya MR, Nimura Y, Kamiya J, Kondo S, Nagino M, Hayakawa N: Clinicopathologic factors influencing survival of patients with bile duct carcinoma: multivariate statistical analysis. World J Surg 1993, 17:653-657.
34. 34 Jarnagin WR, Burke E, Powers C, Fong Y, Blumgart LH: Intrahepatic biliary enteric bypass provides effective palliation in selected patients with malignant obstruction at the hepatic duct confluence. Am J Surg 1998, 175:453-460. This paper discusses biliary enteric bypass options and limitations in proximal biliary tract cancers.
35. 35 Schlitt HJ, Woimann A, Klempnauer J, Oldhafer KJ, Nashan B, Raab R, Pichlmayr R: Peripheral hepatojejunostomy as palliative treatment for irresectable malignant tumors of the liver hilum. Ann Surg 1999, 229:181-186.
36. 36 Ortner M-A EJ, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, et al.: Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998, 114:536-542.
37. 37 Weishaupt KR, Gomer CJ, Dougherty TJ: Identification of singlet oxygen as the cytotoxic agent in photo-inactivation of a murine tumor. Cancer Res 1976, 36:2326-2329.
38. 38 Ducreux M, Liguory CI, Lefebvre JF, Ink O, Choury A, Fritsch J, et al.: Management of malignant hilar biliary obstruction by endoscopy. Results and prognostic factors. Dig Dis Sci 1992, 37:778-783.
39. 39 Polydorou AA, Cairns SR, Dowsett JF, Hatfield ARW, Salmon PR, Cotton PB, Russel RCG: Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. Gut 1991, 32:685-689.
40. 40 Neuhaus SJ, Texler M, Hewett PJ, Watson DI: Port-site metastases following laparoscopic surgery: a review. Br J Surg 1998, 85:735-741. This is a comprehensive review of the experimental and clinical data currently available.
41. 41 Z'graggen K, Birrer S, Maurer CA, Wehrli H, Klaiber C, Baer HU: Incidence of port site recurrence after laparoscopic cholecystectomy for preoperatively unsuspected gallbladder carcinoma. Surgery 1998, 124:831-838.
42. 42 Suzuki K, Kimura T, Ogawa H: Is laparoscopic cholecystectomy hazardous for gallbladder cancer? Surgery 1998, 123:311-314.
43. 43 Ricardo AE, Feig BW, Ellis LM, Hunt KK, Curley SA, MacFadyen BV Jr, Mansfield PFL: Gallbladder cancer and trocar site recurrences. Am J Surg 1997, 174:619-623.